Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target.

Pathology oncology research : POR·2023
Same author

A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.

Journal of cancer research and clinical oncology·2022
Same author

[Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Chirurgie (Heidelberg, Germany)·2022
Same author

Multimodal survival prediction in advanced pancreatic cancer using machine learning.

ESMO open·2022
Same author

[Nodular tumour of the Vas deferens with epithelial structures].

Der Pathologe·2021
Same author

Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Langenbeck's archives of surgery·2021
Same journal

[Connective (tissue) pathology: What brings us together!]

Der Pathologe·2022
Same journal

[Giant cell-containing tumors of bone and differential diagnoses].

Der Pathologe·2022
Same journal

[Automation and application of robotics in the pathology laboratory].

Der Pathologe·2022
Same journal

[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].

Der Pathologe·2022
Same journal

[Artificial intelligence: a solution for the lack of pathologists?]

Der Pathologe·2022
Same journal

[Predictive immunocytochemistry in non-small cell lung carcinoma].

Der Pathologe·2022
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

[Multiple endocrine neoplasia type I].

E Koncz1, K W Schmid

  • 1Institut für Pathologie und Neuropathologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen.

Der Pathologe
|October 21, 2010
PubMed
Summary
This summary is machine-generated.

Multiple endocrine neoplasia type I (MEN1) is a rare genetic syndrome. Early detection of MEN1 gene mutations aids in identifying patients and improves disease management.

Related Experiment Videos

Last Updated: Jun 7, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Context:

  • Multiple endocrine neoplasia type I (MEN1) is a rare hereditary cancer syndrome.
  • It results from germline mutations in the MEN1 tumor suppressor gene.
  • MEN1 is characterized by diverse endocrine and non-endocrine tumors.

Purpose:

  • To review the morphological and clinical features of MEN1-associated neoplasms and lesions.
  • To highlight the significance of genetic testing in MEN1 diagnosis.
  • To emphasize the benefits of integrated genetic and clinical diagnostic approaches.

Summary:

  • MEN1 involves various tumors due to MEN1 gene mutations.
  • Germline mutation detection enables early identification of affected individuals.
  • Combined genetic and clinical diagnostics improve patient outcomes.

Impact:

  • Facilitates early diagnosis and intervention for MEN1 patients.
  • Enhances disease management and quality of life for individuals with MEN1.
  • Provides a comprehensive overview for clinicians and researchers in the field.